151 related articles for article (PubMed ID: 7884415)
1. Collection of peripheral-blood diploid cells from chronic myelogenous leukemia patients early in the recovery phase from myelosuppression induced by intensive-dose chemotherapy.
Kantarjian HM; Talpaz M; Hester J; Feldman E; Korbling M; Liang J; Rios MB; Smith TL; Calvert L; Deisseroth AB
J Clin Oncol; 1995 Mar; 13(3):553-9. PubMed ID: 7884415
[TBL] [Abstract][Full Text] [Related]
2. Percentage of Philadelphia chromosome (Ph)-negative and Ph-positive cells found after autologous transplantation for chronic myelogenous leukemia depends on percentage of diploid cells induced by conventional-dose chemotherapy before collection of autologous cells.
Talpaz M; Kantarjian H; Liang J; Calvert L; Hamer J; Tibbits P; Durett A; Claxton D; Giralt S; Khouri I
Blood; 1995 Jun; 85(11):3257-63. PubMed ID: 7756658
[TBL] [Abstract][Full Text] [Related]
3. Treatment of chronic myelogenous leukemia in accelerated and blastic phases with daunorubicin, high-dose cytarabine, and granulocyte-macrophage colony-stimulating factor.
Kantarjian HM; Talpaz M; Kontoyiannis D; Gutterman J; Keating MJ; Estey EH; O'Brien S; Rios MB; Beran M; Deisseroth A
J Clin Oncol; 1992 Mar; 10(3):398-405. PubMed ID: 1740679
[TBL] [Abstract][Full Text] [Related]
4. Intensive combination chemotherapy and autologous bone marrow transplantation leads to the reappearance of Philadelphia chromosome-negative cells in chronic myelogenous leukemia.
Kantarjian HM; Talpaz M; LeMaistre CF; Spinolo J; Spitzer G; Yau J; Dicke K; Jagannath S; Deisseroth AB
Cancer; 1991 Jun; 67(12):2959-65. PubMed ID: 1675151
[TBL] [Abstract][Full Text] [Related]
5. Collection of 'normal' blood repopulating cells during early hemopoietic recovery after intensive conventional chemotherapy in chronic myelogenous leukemia.
Carella AM; Podesta M; Frassoni F; Raffo MR; Pollicardo N; Pungolino E; Vimercati R; Sessarego M; Parodi C; Rabitti C
Bone Marrow Transplant; 1993 Sep; 12(3):267-71. PubMed ID: 7694724
[TBL] [Abstract][Full Text] [Related]
6. Idarubicin, intermediate-dose cytarabine, etoposide, and granulocyte-colony-stimulating factor are able to recruit CD34+/HLA-DR- cells during early hematopoietic recovery in accelerated and chronic phases of chronic myeloid leukemia.
Carella AM; Frassoni F; Podestá M; Pungolino E; Pollicardo N; Ferrero R; Soracco M
J Hematother; 1994; 3(3):199-202. PubMed ID: 7530135
[TBL] [Abstract][Full Text] [Related]
7. High-dose chemo-radiotherapy followed by autologous Philadelphia chromosome-negative blood progenitor cell transplantation in patients with chronic myelogenous leukemia.
Carella AM; Chimirri F; Podestà M; Pitto A; Piaggio G; Dejana A; Lerma E; Pollicardo N; Vassallo F; Soracco M; Benvenuto F; Valbonesi M; Carlier P; Vimercati R; Prencipe E; Gatti AM; Ferrara RA; Incagliato M; Florio G; Frassoni F
Bone Marrow Transplant; 1996 Feb; 17(2):201-5. PubMed ID: 8640167
[TBL] [Abstract][Full Text] [Related]
8. A phase I-II trial of escalating doses of mitoxantrone with fixed doses of cytarabine plus fludarabine as salvage therapy for patients with acute leukemia and the blastic phase of chronic myelogenous leukemia.
Koller CA; Kantarjian HM; Feldman EJ; O'Brien S; Rios MB; Estey E; Keating M
Cancer; 1999 Dec; 86(11):2246-51. PubMed ID: 10590364
[TBL] [Abstract][Full Text] [Related]
9. Collection of Philadelphia-negative stem cells using recombinant human granulocyte colony-stimulating factor in chronic myeloid leukemia patients treated with alpha-interferon.
Hernández-Boluda JC; Carreras E; Cervantes F; Marín P; Arellano-Rodrigo E; Rovira M; Solé F; Lloveras E; Espinet B; Ocejo A; Montserrat E
Haematologica; 2002 Jan; 87(1):17-22. PubMed ID: 11801461
[TBL] [Abstract][Full Text] [Related]
10. Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine.
Kantarjian HM; O'Brien S; Smith TL; Rios MB; Cortes J; Beran M; Koller C; Giles FJ; Andreeff M; Kornblau S; Giralt S; Keating MJ; Talpaz M
J Clin Oncol; 1999 Jan; 17(1):284-92. PubMed ID: 10458244
[TBL] [Abstract][Full Text] [Related]
11. Comparative analysis of autografting in chronic myelogenous leukemia: effects of priming regimen and marrow or blood origin of stem cells.
Verfaillie CM; Bhatia R; Steinbuch M; DeFor T; Hirsch B; Miller JS; Weisdorf D; McGlave PB
Blood; 1998 Sep; 92(5):1820-31. PubMed ID: 9716614
[TBL] [Abstract][Full Text] [Related]
12. Therapy of acute phase chronic myelogenous leukemia with intensive chemotherapy, blood cell autotransplant and cyclosporine A.
Carella AM; Gaozza E; Raffo MR; Carlier P; Frassoni F; Valbonesi M; Lercari G; Sessarego M; Defferrari R; Guerrasio A
Leukemia; 1991 Jun; 5(6):517-21. PubMed ID: 1676080
[TBL] [Abstract][Full Text] [Related]
13. Intensive conventional chemotherapy can lead to a precocious overshoot of cytogenetically normal blood stem cells (BSC) in chronic myeloid leukemia and acute lymphoblastic leukemia.
Carella AM; Pollicardo N; Raffo MR; Podesta M; Carlier P; Valbonesi M; Lercari G; Vitale V; Gallamini A
Leukemia; 1992 Nov; 6 Suppl 4():120-3. PubMed ID: 1359202
[TBL] [Abstract][Full Text] [Related]
14. Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase.
O'Brien S; Giles F; Talpaz M; Cortes J; Rios MB; Shan J; Thomas D; Andreeff M; Kornblau S; Faderl S; Garcia-Manero G; White K; Mallard S; Freireich E; Kantarjian HM
Cancer; 2003 Sep; 98(5):888-93. PubMed ID: 12942553
[TBL] [Abstract][Full Text] [Related]
15. Use of granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with hydroxyurea as post-transplant therapy in chronic myelogenous leukemia patients autografted with unmanipulated hematopoietic cells.
Carlo-Stella C; Regazzi E; Andrizzi C; Savoldo B; Garau D; Montefusco E; Vignetti M; Mandelli F; Rizzoli V; Meloni G
Haematologica; 1997; 82(3):291-6. PubMed ID: 9234574
[TBL] [Abstract][Full Text] [Related]
16. Intensive chemotherapy in patients with chronic myelogenous leukaemia (CML) in accelerated or blastic phase--a report from the Swedish CML Group.
Axdorph U; Stenke L; Grimfors G; Carneskog J; Hansen J; Linder O; Ljungman P; Löfvenberg E; Malm C; Simonsson B; Turesson I; Vilén L; Udén AM; Björkholm M;
Br J Haematol; 2002 Sep; 118(4):1048-54. PubMed ID: 12199784
[TBL] [Abstract][Full Text] [Related]
17. Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-alpha and low-dose cytarabine.
Kantarjian HM; Keating MJ; Estey EH; O'Brien S; Pierce S; Beran M; Koller C; Feldman E; Talpaz M
J Clin Oncol; 1992 May; 10(5):772-8. PubMed ID: 1569449
[TBL] [Abstract][Full Text] [Related]
18. FLANG (fludarabine + cytosine arabinoside + novantrone + G-CSF) induces partial remission in lymphoid blast transformation of Ph+chronic myelogenous leukaemia.
Martinelli G; Testoni N; Zuffa E; Visani G; Zinzani PL; Zaccaria A; Farabegoli P; Arpinati M; Amabile M; Tura S
Leuk Lymphoma; 1996 Jun; 22(1-2):173-6. PubMed ID: 8724545
[TBL] [Abstract][Full Text] [Related]
19. Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia.
Feldman EJ; Alberts DS; Arlin Z; Ahmed T; Mittelman A; Baskind P; Peng YM; Baier M; Plezia P
J Clin Oncol; 1993 Oct; 11(10):2002-9. PubMed ID: 8410125
[TBL] [Abstract][Full Text] [Related]
20. Mobilization of peripheral stem cells with intensive chemotherapy (ICE regimen) and G-CSF in chronic myeloid leukemia.
Boqué C; Petit J; Sarrá J; Cancelas JA; Muñoz J; Español JI; de la Banda E; Aventin A; Berlanga J; Ferrá C; Amill B; Torrico C; Azqueta C; Llucià M; García J; Grañena A
Bone Marrow Transplant; 1996 Nov; 18(5):879-84. PubMed ID: 8932840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
